Comment
its stock of pre-printed media from 150 different variants to under eight, reducing warehousing footprint (100 pallets down to 10), logistics complexity and cost. In addition to the measurable reduction in stock volume and wastage, further environmental benefits include fewer transport miles, reduced use of forklifts in the warehouse and less landfill. Beyond material optimisation, digital printing is also flexible, supporting the use of eco-friendly recyclable substrates and enabling the creation of 2D codes that unlock further sustainability gains. Smart 2D codes are key to the adoption of electronic Patient Information Leaflets (ePIL), right-sized packaging and improved recyclability. They also enhance supply chain transparency, with additional information to help customers understand and report on relevant Scope 3 emissions.
SMART 2D CODES: ENHANCING SAFETY, COMPLIANCE AND PATIENT TRUST Smart 2D codes are also regarded as the future for delivering the next level of data integrity required in an industry facing increasing regulatory and public scrutiny. Product recalls are both expensive and hugely damaging to reputation and
create potentially serious patient risk. Error reduction is key to ensuring consistent product packaging, safeguarding patients and, as a result, protecting brand reputation. Validated digital printed solutions can improve patient safety at every stage of the process, enhancing print clarity and enabling serialisation and traceability through smart 2D codes. Integrated inspection systems further support this by ensuring every product is safe and correctly labelled, automatically fl agging any issues in real time.
Safety and compliance are also enhanced by the adoption of on- or near-line digital printing which supports the move to smaller batch sizes and enable the late-stage customisation of pharmaceutical packaging, allowing pharma companies to manage diverse global market needs, from language to local regulatory requirements, without incurring additional cost or downtime and avoid the risk of obsolete stock with out-of- date information.
FROM COMPLIANCE TO COMPETITIVE EDGE: WHY CONNECTED PACKAGING IS A STRATEGIC IMPERATIVE The benefits of digitalisation in pharmaceutical packaging are clear and
measurable. Pharma manufacturers gain faster time-to-market, lower operational costs and improved sustainability metrics. It can reduce rework and rejects, enhance regulatory confidence and build a platform for scalable global innovation. Most importantly, manufacturers move from reactive problem-solving to proactive performance, turning pharmaceutical packaging into a platform for efficiency, resilience and competitive advantage. This step change in performance can be achieved seamlessly with the right timing and partner. Manufacturers should look for a partner with proven pharmaceutical expertise, validated technology, and a collaborative approach. A strong partner will offer connected, cloud-enabled solutions, and support compliance during revalidation windows, while aligning with sustainability goals and providing integration support. Leveraging planned revalidation windows to undertake a digital upgrade allows manufacturers to innovate without slowing down production. The result is a leaner, more agile operation with measurable ROI typically achieved within the industry’s two-year benchmark.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46
